BNOX Bionomics
- 1.000
- +0.034+3.49%
- 1.020
- +0.020+2.00%
Bionomics News
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersOneMedNet (NASDAQ:ONMD) shares moved upwards by 75.9% to $1.39 during Tuesday's after-market session. The market value of their outstanding shares is at $44.8 million. Aesthetic Medical Intl (N
Buy Rating Affirmed for Bionomics' BNC210 Following Promising PTSD Study Results
Bionomics's BNC210 Shows Promise for PTSD Treatment: A Buy Rating Analysis
Bionomics Reveals Detailed Data From PTSD Trial, Stock Soars
Thursday, Bionomics Limited (NASDAQ:BNOX) released a full dataset analysis from its Phase 2b ATTUNE trial of BNC210 in patients with post-traumatic stress disorder (PTSD).In September 2023, Bionomics
Express News | Bionomics Shares Are Trading Higher After the Company Disclosed Results of Phase 2b ATTUNE Trial of BNC210 in Post-traumatic Stress Disorder
Express News | Bionomics Disclosed Results Of The Full Dataset Analysis From ATTUNE Phase 2b Trial Of BNC210 In Patients With Post-Traumatic Stress Disorder
Bionomics Reports Results of the Full Dataset Analysis From ATTUNE Phase 2b Trial of BNC210 in Patients With Post-Traumatic Stress Disorder
BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications.
Global Post-traumatic Stress Disorder (PTSD) Drug Pipeline Landscape Report 2024 Featuring Tonix Pharmaceuticals, Pop Test Oncology, H. Lundbeck, Bionomics, and Alto Neuroscience
Bionomics to Present at the 2024 BIO CEO & Investor Conference
ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric
Ocugen, Community Health Systems Among Healthcare Movers
Bionomics: A Strong Buy on Clinical and Regulatory Milestones
Wall Street Set to Open Higher in Monday Trading Ahead of Economic Indicators Data
US stocks look set to open the week on a positive note, rising higher in Monday's premarket session higher ahead of the index of leading economic indicators for December that is to be released later i
XPEV, BILI and ROMA Among Pre-market Losers
US Futures Poised to Open Week Higher, Leading Economic Indicators on Tap
US stock futures rose ahead of the index of leading economic indicators for December, which is slated for release at 10 a.m. ET and is forecast to be down 0.3%, according to Investing.com The Dow Jone
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersMSP Recovery (NASDAQ:LIFW) shares rose 23.1% to $1.49 during Monday's pre-market session. The market value of their outstanding shares is at $21.4 million. 60 Degrees (NASDAQ:SXTP) stock moved
Bionomics Provides a Review of 2023 and of 2024 Plans
Positive Phase 2b data announced for BNC210 on reduction of total symptom severity and multiple symptom clusters in post-traumatic stress disorder (PTSD), with a discussion with the U.S. Food & Drug Administration
Bionomics to Present at Biotech Showcase 2024
ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric
HC Wainwright & Co. Reiterates Buy on Bionomics, Maintains $8 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Bionomics (NASDAQ:BNOX) with a Buy and maintains $8 price target.
Bionomics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 12/07/2023 504.18% HC Wainwright & Co. → $8 Reiterates Buy → Buy 09/28/2023 655.23% Maxim Group $7 → $10 M
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersReshape Lifesciences (NASDAQ:RSLS) stock moved upwards by 17.9% to $0.31 during Wednesday's after-market session. The market value of their outstanding shares is at $4.0 million. Monopar Therap
Analysis
Price Target
No Data
